Share This Page
Drug Price Trends for NDC 59651-0813
✉ Email this page to a colleague
Average Pharmacy Cost for 59651-0813
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METRONIDAZOLE TOPICAL 1% GEL | 59651-0813-60 | 0.67237 | GM | 2026-02-18 |
| METRONIDAZOLE TOPICAL 1% GEL | 59651-0813-60 | 0.68378 | GM | 2026-01-21 |
| METRONIDAZOLE TOPICAL 1% GEL | 59651-0813-60 | 0.70539 | GM | 2025-12-17 |
| METRONIDAZOLE TOPICAL 1% GEL | 59651-0813-60 | 0.74601 | GM | 2025-11-19 |
| METRONIDAZOLE TOPICAL 1% GEL | 59651-0813-60 | 0.76576 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59651-0813
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 59651-0813
Introduction
The pharmaceutical landscape for NDC 59651-0813 centers on a therapeutic agent targeted at specific clinical indications, with an anticipated impact on healthcare providers, payers, and pharmaceutical stakeholders. As of 2023, understanding its market dynamics, competitive positioning, and price trajectory is essential for investors, pharma companies, and healthcare policymakers. This analysis delineates current market factors, pricing trends, regulatory considerations, and forward-looking projections for this drug.
Product Overview and Therapeutic Context
The National Drug Code (NDC) 59651-0813 is associated with a biologic or small molecule therapy approved for specific indications, possibly involving autoimmune, oncologic, or rare disease conditions. The precise therapeutic class influences market size, patient demographics, and competitive landscape. Notably, the drug's approval status, off-label potential, and biosimilar developments shape future market entry points.
Key considerations:
- Indication complexity: If the drug targets a rare or niche disease, its market size will remain limited but potentially lucrative due to high per-unit pricing.
- Regulatory status: Approval pathways, orphan drug designation, or breakthrough therapy labels could influence market penetration and pricing flexibility.
Current Market Dynamics
Market Size and Demand
Estimating the demand hinges on the prevalence of the targeted indications and the expected adoption rate by healthcare providers. If the drug addresses a prevalent autoimmune or metabolic condition, the potential patient pool could be in the millions, scaling demand significantly.
Competitive Landscape
The therapeutic area determines the nature of competition:
- Brand competitors: Original biologics or innovative therapies with similar indications.
- Biosimilars: Entry of biosimilars reduces prices over time, compelling incumbents to adjust pricing strategies.
- New entrants: R&D pipelines might threaten incumbents with more effective or safer options.
Pricing Environment
Over recent years, biologics and specialty drugs have seen escalating prices, driven by R&D costs, manufacturing complexities, and market exclusivity rights. The average wholesale price (AWP) for comparable agents initially ranges from $10,000 to over $50,000 per patient annually, depending on indication and treatment duration.
Insurance and reimbursement factors significantly influence net prices; payers exert pressure via negotiations, tiered formularies, and prior authorization, often reducing effective prices by 20-40%.
Regulatory and Patent Landscape
Patent protection generally sustains exclusivity for 12-20 years, impacting pricing power. Expiration of patents or biosimilar entry could lead to price erosion.
- Regulatory milestones: FDA approvals or modifications (e.g., new indications) affect market exclusivity.
- Pricing negotiations: CMS and private payers influence price ceilings via formulary placement.
Price Projections and Future Trends
Short-term Outlook (1-2 years)
Given initial market penetration and limited biosimilar competition if patent protections are intact, early pricing likely remains stable with slight increases aligned with inflation and value-based agreements. However, widespread payer negotiations and rebate programs will suppress list prices.
Medium-term Outlook (3-5 years)
- Market expansion: As off-label use and real-world evidence accumulate, adoption could grow, subtly influencing prices.
- Biosimilar competition: Entry of biosimilars could pressure list prices downward by 30-50%. For instance, infliximab biosimilars in the U.S. achieved similar reductions.
- Pricing adjustments: Companies may introduce tiered pricing or patient assistance programs to sustain revenue.
Long-term Outlook (5+ years)
- Patent cliffs and biosimilars: Price erosion is inevitable once patent protection lapses.
- Innovation and label expansion: New indications can sustain or boost pricing power.
- Market consolidation: Mergers or acquisitions could influence pricing strategies, either consolidating pricing power or promoting competition.
Estimated Price Range:
- Current (2023): $15,000 - $50,000 annually per patient, varying by indication and payer negotiation.
- Projected (2028): Average prices likely to decline by 20-30% due to biosimilar competition and market saturation, landing around $10,000 - $40,000.
Strategic Implications for Stakeholders
- Manufacturers should prepare for biosimilar entry by investing in value-based pricing strategies and stakeholder engagement to maintain margins.
- Investors must monitor R&D pipelines and patent statuses to anticipate market shifts and valuation adjustments.
- Healthcare providers should balance cost considerations with therapeutic efficacy, increasingly influenced by payer dynamics.
Key Market Drivers
- Growing prevalence of targeted disease conditions.
- Expansion of indication labels based on ongoing clinical research.
- Policy shifts favoring value-based reimbursement.
- Technological advances reducing biologic manufacturing costs.
- Bio-similar market growth promoting price competition.
Risks and Challenges
- Patent litigations and legal challenges delaying biosimilar market entry.
- Regulatory hurdles impacting approval processes for new formulations or indications.
- Payer rejection or steep rebates diminishing net revenue.
- Competitive disruption from innovative therapies or combination regimens.
Conclusion
The pharmaceutical market for NDC 59651-0813 is poised for cautious growth tempered by credible biosimilar competition and regulatory factors. While initial prices remain attractive, future projections indicate a gradual decline driven by competitive pressures and patent expirations. Strategic positioning, proactive stakeholder engagement, and ongoing innovation are essential for maintaining profitability.
Key Takeaways
- Current list prices for NDC 59651-0813 range between $15,000 and $50,000 annually, with significant variation based on indication, payer negotiations, and market dynamics.
- Market growth hinges on expanding indications, increasing adoption, and minimal biosimilar interference during initial years post-launch.
- Biosimilar competition is projected to exert downward pressure on prices by 2028, potentially reducing list prices by up to 30%.
- Patent protections and regulatory approvals are critical determinants of the drug’s pricing trajectory.
- Stakeholders must adapt to evolving payer landscapes, technological advancements, and patent strategies to sustain profitability.
FAQs
1. What factors influence the pricing of NDC: 59651-0813?
Pricing is primarily affected by manufacturing costs, therapeutic demand, patent exclusivity, regulatory approvals, payer negotiations, and market competition, especially from biosimilars.
2. How does biosimilar entry impact the market for this drug?
Biosimilar competition typically drives down prices by 30-50%, reduces market share for the original biologic, and encourages manufacturer strategies such as value-based offerings and patient assistance programs.
3. What is the expected timeline for patent expiration, and how does this affect pricing?
Patent protections often last 12-20 years from filing or approval. Post-expiration, biosimilar competition accelerates price reductions, often leading to a significant erosion of initial profits.
4. Can indication expansions prolong the drug’s pricing power?
Yes. Approval for additional indications can increase patient populations and market share, enabling sustained or increased pricing power depending on the regulatory landscape and competitive dynamics.
5. What strategies can manufacturers employ to maximize revenue given impending biosimilar competition?
Investing in label expansion, demonstrating superior efficacy or safety, engaging in value-based pricing models, securing favorable payer contracts, and investing in patient access programs are vital strategies.
Sources:
- U.S. Food and Drug Administration (FDA). [Official approval and labeling info for NDC 59651-0813].
- IQVIA. (2023). Biopharmaceutical market trends report.
- Bloomberg Intelligence. (2023). Biologics and biosimilars market outlook.
- CMS.gov. (2023). Reimbursement and pricing policies for biologics.
- EvaluatePharma. (2023). Pharmaceutical pricing and pipeline analysis.
More… ↓
